We are investigating Amneal Pharmaceuticals, Inc. (AMRX) (“Amneal” or the “Company”) for potential violations of the federal securities laws.
On July 10, 2019, Amneal cut its 2019 core earnings forecast, citing the uncertain supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV’s EpiPen. Amneal also cited delays in regulatory approvals and launches as other reasons for the lowered forecast. On this news, Amneal’s stock price fell $2.45 per share, or 35.98%, to close at $4.36 per share on July 10, 2019.